CMS issued a permanent, product-specific J-code for Iheezo, an ocular surface anesthesia gel, according to a Harrow press release.
The code, J2403, goes into effect April 1.
Iheezo is a single-patient-use ophthalmic gel preparation of chloroprocaine hydrochloride approved by the FDA in September 2022. Clinical trials showed that participants treated with Iheezo did not require supplemental treatment to complete surgical procedures, according to the release.
“We are committed to the accessibility of new therapies that benefit eye care professionals and the patients they serve,” Mark